ciprofloxacin · Alk Abello · NDA 207986
Otiprio
Earliest generic entry, as listed
27 Nov 2038
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 11246863.
Listed patents · 8 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 11246863 | drug product · sets the listed date | 27 Nov 2038 |
| US 11040004 | use U-2252 | 12 Nov 2037 |
| US 9220796 | drug product | 1 Jul 2035 |
| US 8318817 | use U-1792 | 27 Apr 2030 |
| US 9233068 | drug product | 11 Dec 2029 |
| US 11369566 | drug product | 21 Apr 2029 |
| US 9205048 | use U-1793 | 21 Apr 2029 |
| US 9603796 | drug substance, drug product, use U-2252 | 21 Apr 2029 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 1
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 207986 · 001 · RLD · discontinued | injectable, suspension, otic | 6% (60MG/ML) | 27 Nov 2038 |